Singapore G-Protein Coupled Receptor (GPCR) Market Size & Outlook, 2026-2034

Singapore G-Protein Coupled Receptor (GPCR) Market Insights

As highlighted in Deep Market Insights analysis, the Singapore G-Protein Coupled Receptor (GPCR) Market, worth USD 17.97 Million in 2025, is forecasted to achieve USD 31.85 Million by 2034.
The Singapore market is anticipated to grow at a CAGR of 6.5% during the period 2026–2034.
By 2025, GPCR Cell Lines represented the largest share of the By Product Type market size.
GPCR Cell Lines is expected to remain the key growth driver within By Product Type, registering the fastest CAGR during the forecast period.

As of 2025, Singapore held 0.45% of the global G-Protein Coupled Receptor (GPCR) Market size.
By 2034, United States is anticipated to capture the largest share of the global G-Protein Coupled Receptor (GPCR) Market.
In Asia Pacific, China is expected to lead the regional G-Protein Coupled Receptor (GPCR) Market size by 2034.
India will remain the fastest-growing market in Asia Pacific, reaching USD 291 Million by 2034.

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 17.97 Million
Market Size In 2034	USD 31.85 Million
Largest segment	GPCR Cell Lines
Units	Revenue in USD Million
CAGR	6.5% (2026-2034)
Segmnetation Covered
By Product Type	GPCR Cell Lines Detection & Assay Kits Cell Culture Reagents Ligands (Agonists, Antagonists, Modulators) GPCR Libraries & Screening Panels
By Application	Drug Discovery & Target Identification Central Nervous System Research Oncology Research Cardiovascular Disease Research Metabolic Disorder Research Inflammation & Immunology Research Respiratory Disease Research
By End-User	Pharmaceutical Companies Biotechnology Companies Contract Research Organizations (CROs) Academic & Research Institutes Government Research Laboratories
By Technology Platform	Cell-Based GPCR Assays Label-Free Assays Reporter Gene Assays Fluorescence-Based Assays Luminescence-Based Assays Biosensor-Based Assays
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

By Product Type	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
GPCR Cell Lines	XX.x	XX.x	XX.x	7.79	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Detection & Assay Kits	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Cell Culture Reagents	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Ligands (Agonists, Antagonists, Modulators)	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
GPCR Libraries & Screening Panels	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By Application	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Drug Discovery & Target Identification	XX.x	XX.x	XX.x	5.31	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Central Nervous System Research	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Oncology Research	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Cardiovascular Disease Research	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Metabolic Disorder Research	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Inflammation & Immunology Research	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Respiratory Disease Research	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By End-User	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Pharmaceutical Companies	XX.x	XX.x	XX.x	6.41	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Biotechnology Companies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Contract Research Organizations (CROs)	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Academic & Research Institutes	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Government Research Laboratories	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By Technology Platform	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Cell-Based GPCR Assays	XX.x	XX.x	XX.x	5.39	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Label-Free Assays	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Reporter Gene Assays	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Fluorescence-Based Assays	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Luminescence-Based Assays	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Biosensor-Based Assays	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x